ERBB2 and breast carcinoma: Treatment guidelines recommend the use of gene expression tools to inform adjuvant chemotherapy selection for patients with early-stage HR+/HER2- breast cancers, with intermediate risk defined using clinical and histopathologic methods29,37,41,82–84.